Stock Overview

Dianthus Therapeutics Inc. (DNTH)

NASDAQ · Healthcare · Biotechnology

Dianthus Therapeutics Inc. is a Healthcare company with a market capitalization of $5.84B.

Market Cap
$5.84B
Price/Sales
3,065.7
Price/Book
5.1
EV/EBITDA
-7.2
Beta
0.08
EPS (TTM)
$-4.24
Profit Margin
-847.5%
ROE
-26.1%
Short % of Float
16.5%
Days to Cover
8.9
52W High
$112.64
52W Low
$20.25

5-Year Price History

Latest Annual Financials · FY ending December 31, 2025

Revenue
$2.04M
Gross Profit
$2.04M
Operating Income
-$177.93M
Net Income
-$162.34M
Free Cash Flow
-$129.27M
Total Debt
$367.00K
Cash & Equivalents
$51.09M
Shareholder Equity
$493.40M

Recent Quarterly Earnings (EPS)

QuarterReportedActual EPSEstimateSurprise
Q2 2026August 4, 2026$-0.90$-0.93+3.2%
Q1 2026May 5, 2026$-0.85$-1.10+22.7%
Q4 2025March 9, 2026$-1.43$-1.03-38.6%
Q3 2025November 5, 2025$-0.97$-0.86-12.8%
Q2 2025August 7, 2025$-0.88$-0.86-2.3%
Q1 2025May 12, 2025$-0.82$-0.71-15.5%

Short Interest

FINRA-reported short interest for semi-monthly settlement dates, published about nine business days after each settlement. Share counts are adjusted to the current split basis.

SettlementShares Short% of Shares OutDays to CoverChange
July 15, 20269,220,02819.20%8.9-3.3%
June 30, 20269,533,15119.85%5.5+36.6%
June 15, 20266,979,12614.53%5.7+4.3%
May 29, 20266,690,11013.93%10.9+4.0%
May 15, 20266,431,39813.39%14.3-1.9%
April 30, 20266,552,52017.34%14.1-0.2%
April 15, 20266,564,59917.37%8.3-27.6%
March 31, 20269,069,81124.00%7.4-1.4%

Other Biotechnology Stocks

Frequently Asked Questions

What is Dianthus Therapeutics Inc.'s market cap?

As of August 13, 2026, Dianthus Therapeutics Inc. (DNTH) has a market capitalization of $5.84B.

Does Dianthus Therapeutics Inc. pay a dividend?

Dianthus Therapeutics Inc. does not currently pay a dividend.

What sector is DNTH in?

Dianthus Therapeutics Inc. is in the Healthcare sector, specifically the Biotechnology industry.

What is Dianthus Therapeutics Inc.'s short interest?

As of the July 15, 2026 FINRA settlement, 9,220,028 DNTH shares were sold short, or 19.20% of shares outstanding. Days to cover: 8.9. FINRA publishes short interest twice a month, about nine business days after each settlement date.

What was Dianthus Therapeutics Inc.'s revenue?

In its latest reported fiscal year (ending December 31, 2025), Dianthus Therapeutics Inc. reported revenue of $2.04M and net income of -$162.34M.

Ask your own questions about DNTH

Try mrmarket.ai free

Data as of August 13, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.